1. GSF: Groupe Sarcome Français
GETO: Groupe d’Etudes des Tumeurs Osseuses
Paris- RP
Reims
Rennes
Tours
Marseille
Montpellier
Lyon
Nice
Lille
Strasbourg
Bordeaux
Dijon
Besançon
Nantes
Toulouse
Poitiers
Angers
Nancy
Caen
Rouen
N = 40 institutions
Sarcoma Database:
2500 pts
Frozen tissue bank:
1000 sarcomas
Villejuif
Clermont-Ferrand

2. Sarcome 01 Euro-Ewing 99 EORTC SFCE GPOH UKCCSG Total N 83 475 673 332
PI : Dr O. Oberlin – Villejuif
EORTC
SFCE
GPOH
UKCCSG
Total N 83
475
673
332
1563
% ® Patients
53 %
40 %
37 % 50
100
150
200
250
300
350
400
450
500
Jan-00
Apr-00
Jul-00
Oct-00
Jan-01
Apr-01
Jul-01
Oct-01
Jan-02
Actual R1
Expected R1
R1 randomization
May-02
Aug-02
Nov-02
Feb-03
May-03
Aug-03
Nov-03
Feb-04
May-04
Aug-04
Nov-04
Feb-05
May-05
Aug-05

3. Sarcome 02 PALSAR II Main end-point: overall survival
PI : Dr N B BUI – Bordeaux
Main end-point: overall survival
Statistical hypothesis: 3-yr OS: 40% vs 15% (N per arm: 50)
October 05: N = 184 pts N® = 60 patients

4. Sarcome 03 Osteosarcoma Localized operable osteosarcoma API-AI regimen
PI : A Le Cesne – Villejuif
Localized operable
osteosarcoma
API-AI regimen
4 CT courses
N = 39 evaluable pts
Main end-point: histological response rate
Statistical hypothesis: Simon two step
at least 14/39 good histological response
Analysis ongoing ASCO 06

5. Sarcome 04 EWING D1 D8 D15 D21 D28/1 D8 D15 D21 D28 October 2005 = 25
PI : O Oberlin – Villejuif
D D D D21 D28/ D8 D D D28
CDDP
VP-16
Main end-point: Objective response rate
Statistical hypothesis: Simon: at least 6/29 OR
October 2005 = 25

6. Sarcome 05 Desminib Progressive AF/Desmoid T Glivec®: 400 mg/d
PI : JY Blay – Lyon
Progressive AF/Desmoid T
Glivec®: 400 mg/d
800 mg/d if PD
Duration: one year
Main end-point: 3-month PFS
Statistical hypothesis: Simon two step: patients
at least 7 patients not PD at 3 months
Secondary end-point: 12-m PFS, OS, tolerance, OR
Analysis ongoing ASCO 06

7. Sarcome 06: Angiotax Angiosarcoma 2nd/3rd CT line
PI : N Penel – Lille
Angiosarcoma
2nd/3rd CT line
Weekly taxol: 80 mg/w
3 weeks on, 1 off
Main end-point: Objective response rate
Statistical hypothesis: Simon two step: patients
at least 6/25 OR
Secondary end-point: PFS, OS, tolerance
Translational research

8. Sarcome 07 Taxogem ® phase II Leiomyosarcoma Uterine vs other
PI : F. Duffaud – Marseille P. Pautier - Villejuif
® phase II
Leiomyosarcoma
Uterine vs other
2nd CT line
N =
Main end-point: OR
Secondary end-point: PFS, OS, tolerance, QOL

9. Sarcome 08:Adjuvant GIST
EORTC 62024
PI (FSG) : A Le Cesne – Villejuif
Participating French centers : 42
November 2005
N = 121

10. Advanced GIST – BFR 14 trial French Sarcoma Group (June 2002)
PI : J.Y Blay – Lyon A. Le Cesne - Villejuif
Stop
Gleevec® Gleevec® R
Gleevec®
Day months
+/- surgery
N patients included in October 2005: 268
N randomized patients (after 1 year) 58 (early interruption)
Stop imatinib arm: 32
imatinib arm: 26
N randomized patients (after 3 years) 12 1 2